Advanced Neuromodulation (NASDAQ:ANSI)
Historical Stock Chart
From Jun 2019 to Jun 2024
![Click Here for more Advanced Neuromodulation Charts. Click Here for more Advanced Neuromodulation Charts.](/p.php?pid=staticchart&s=N%5EANSI&p=8&t=15)
ANS Introduces Industry's First Curved Leads Designed to Focus
Stimulation for Pain Relief
New Leads Facilitate Precise Lead Placement and More Efficient Use of ANS'
Neurostimulation Systems
PLANO, Texas, Sept. 1 /PRNewswire-FirstCall/ -- Advanced Neuromodulation
Systems, Inc. (NASDAQ:ANSI) (ANS) today introduced its line of C-Series
Lamitrode(R) leads, the market's first set of leads to mimic the curve of the
epidural space -- the space between the spine and the spinal cord. These
curved leads are designed to direct stimulation toward the spinal cord and to
minimize unwanted stimulation in the posterior epidural space. Moreover, the
C-Series Lamitrode leads facilitate lead insertion and placement.
(Photo: http://www.newscom.com/cgi-bin/prnh/20040901/DAW008 )
"There is an observable and dramatic positive difference when placing ANS'
C-Series leads during spinal cord stimulation cases," said Dr. F. Richard
Jordan. "The curved design makes placement easier, decreases the chance for
lead movement and helps to reduce overall operation time."
The C-Series leads feature two rows of electrodes with wide lateral spacing to
enhance bilateral stimulation. The electrodes are shielded to focus the
electrical current in one direction. This unidirectional current makes it
possible to provide therapy at lower power levels, resulting in greater system
efficiency and longer battery life.
"ANS' engineering team designed the C-Series Lamitrode leads to benefit the
physician and patient," said ANS President and CEO Chris Chavez. "With this
new product, we continue to demonstrate technology leadership in the rapidly
growing neuromodulation market."
The C-Series Lamitrode leads extend ANS' already broad line of neurostimulation
leads. The breadth of this line allows physicians to select the lead that best
fits each patient's unique anatomical needs. With the choices of percutaneous,
surgical, and trial leads, physicians can facilitate precise stimulation and
satisfy placement preferences without compromising performance.
About chronic pain
Chronic pain affects an estimated 50 million Americans, of whom more than half
are partially or totally disabled. At present, approximately $100 billion are
spent in the U.S. on the diagnosis and treatment of chronic pain, which
represents the most common indication for spinal cord stimulation therapy. The
106th U.S. Congress has declared this the "Decade of Pain Control and
Research," helping to bring spinal cord stimulation to the forefront as a
viable and effective option in the treatment of chronic pain.
About Advanced Neuromodulation Systems (ANS)
Advanced Neuromodulation Systems, Inc. designs, develops, manufactures and
markets implantable systems used to manage chronic intractable pain and other
disorders of the central nervous system. A technology leader in the
neuromodulation industry, ANS offers a family of proprietary neurostimulation
devices and implantable drug pumps for an expanding range of therapeutic
applications. ANS was recently named among FORTUNE's 100 Fastest Growing
Companies and has been recognized among Forbes' 200 Best Small Companies for
two consecutive years. Frost & Sullivan also honored the company with its
Product Innovation Award. ANS is financially sound and growing, reporting 2003
net revenue of $91.1 million, up 37 percent from 2002. Additional information
is available at http://www.ans-medical.com/ .
http://www.newscom.com/cgi-bin/prnh/20040901/DAW008
DATASOURCE: Advanced Neuromodulation Systems, Inc.
CONTACT: Megan Lozito, +1-972-716-0500, ext. 14, or
, for Advanced Neuromodulation Systems, Inc.
Web site: http://www.ans-medical.com/